Market Place
Sourcing Support
Madrigal Pharmaceuticals to Present Rezdiffra™ Abstracts at AASLD
30 Oct 2024 //
GLOBENEWSWIRE
Madrigal Pharma to Participate in Morgan Stanley Global Healthcare Conference
26 Aug 2024 //
GLOBENEWSWIRE
Madrigal Pharmaceuticals To Participate In Morgan Stanley Healthcare Conference
26 Aug 2024 //
GLOBENEWSWIRE
Madrigal Pharmaceuticals Reports Q2 2024 Results And Corporate Updates
07 Aug 2024 //
GLOBENEWSWIRE
Madrigal`s Rezdiffra off to strong start, but `bumpiness` is coming: analyst
07 Aug 2024 //
FIERCE PHARMA
Madrigal Pharma To Release Q2 2024 Results On August 7
24 Jul 2024 //
GLOBENEWSWIRE
Madrigal Presents MAESTRO-NASH Data On Rezdiffra™ At EASL Congress
06 Jun 2024 //
GLOBENEWSWIRE
Lilly pads tirzepatide`s MASH win with detailed fibrosis data
06 Jun 2024 //
FIERCE PHARMA
Madrigal`s Rezdiffra Data At EASL On NASH/MASH And Health Economics
29 May 2024 //
GLOBENEWSWIRE
Madrigal builds launch infrastructure for MASH drug Rezdiffra
08 May 2024 //
FIERCE PHARMA
Madrigal Pharmaceuticals Q1 2024 Results And Corporate Updates
07 May 2024 //
GLOBENEWSWIRE
Madrigal Pharmaceuticals launches Rezdiffra in the US
09 Apr 2024 //
GLOBENEWSWIRE
Docs sing praises of Madrigal`s Rezdiffra, predict rapid uptake
08 Apr 2024 //
FIERCE PHARMA
Revarazan Hcl For Acute Gastritis, Chronic Gastritis Gastric Mucosal Lesions
28 Mar 2024 //
PRESS RELEASE
Amber Pharmacy Selected to Dispense Rezdiffra™ to Treat NASH
25 Mar 2024 //
BUSINESSWIRE
After MASH nod, Madrigal plots $600M stock sale to support launch
19 Mar 2024 //
FIERCE PHARMA
Galmed Announces Grant of Patent for Combination of Aramchol with Resmetirom
15 Mar 2024 //
PR NEWSWIRE
FDA approves Madrigal drug as first treatment for common NASH liver disease
15 Mar 2024 //
CNBC
Madrigal Pharmaceuticals Announces EMA Validation of its MAA for Resmetirom
05 Mar 2024 //
GLOBENEWSWIRE
Madrigal says new data show resmetirom has `broad` effects in NASH
11 Nov 2023 //
GLOBENEWSWIRE
FDA gives Madrigal`s NASH drug priority review, no AdComm
14 Sep 2023 //
FIERCE BIOTECH
Madrigal Announces NDA Acceptance and Priority Review of NDA for Resmetirom
13 Sep 2023 //
PRESS RELEASE
Madrigal Completes Submission of NDA Seeking Accelerated Approval of Resmetirom
17 Jul 2023 //
GLOBENEWSWIRE
Madrigal seeks accelerated approval for experimental NASH treatment
01 Jul 2023 //
ENDPTS
Madrigal Pharmaceuticals Announces $300+ Million in Financing Events
21 Dec 2022 //
GLOBENEWSWIRE
Madrigal Pharmaceuticals Breaks Through In NASH With Late-Stage Win
20 Dec 2022 //
GLOBENEWSWIRE
Madrigal To Announce Results from the Phase 3 MAESTRO-NASH Study of Resmetirom
18 Dec 2022 //
PRESS RELEASE
Madrigal Pharma Presents Late-Breaking PIII NASH Data at EASL
25 Jun 2022 //
GLOBENEWSWIRE
Madrigal adds to safety data for NASH drug
01 Feb 2022 //
BIOPHARMADIVE
Madrigal To Announce Topline Results from the Phase 3 Study of Resmetirom
29 Jan 2022 //
GLOBENEWSWIRE
Madrigal Announces Three Abstracts Accepted by The Liver Meeting Experience™
01 Oct 2020 //
GLOBENEWSWIRE
